Arch Therapeutics
Abrams has more than 25 years of experience as a CFO to numerous public and private companies. He has also served as a principal investor; investment banker; merchant banker; strategic and financial advisor; and board member. He is a graduate of UMass Amherst and the University of Chicago.
This person is not in any offices
Arch Therapeutics
Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care.